G Finazzi

Summary

Country: Italy

Publications

  1. ncbi Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    J Autoimmun 15:101-5. 2000
  2. ncbi Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome?
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Haemostasis 30:57-62. 2000
  3. ncbi Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups
    R Bassan
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Hematol J 2:117-26. 2001
  4. ncbi The epidemiology of the antiphospholipid syndrome: who is at risk?
    G Finazzi
    Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Curr Rheumatol Rep 3:271-6. 2001
  5. ncbi Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG)
    S Cortelazzo
    Divisione di Ematologia, Ospedali Riuniti di Bergamo, Italy
    Ann Oncol 10:1433-40. 1999
  6. ncbi Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinic
    R Bassan
    Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy
    Haematologica 84:1088-93. 1999
  7. ncbi Treatment of essential thrombocythemia with special emphasis on leukemogenic risk
    G Finazzi
    Division of Hematology, Ospedali Riuniti, Largo Barozzi 1, I 24100 Bergamo, Italy
    Ann Hematol 78:389-92. 1999
  8. ncbi Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI)
    S Cortelazzo
    Division of Hematology, Ospedali Riuniti di Bergamo, Italy
    Ann Oncol 10:427-32. 1999
  9. ncbi The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 81:695-700. 1999
  10. ncbi Prothrombin as cofactor for antiphospholipids
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Lupus 7:S37-40. 1998

Collaborators

Detail Information

Publications26

  1. ncbi Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    J Autoimmun 15:101-5. 2000
    ..These data do not allow to recommend the measurement of anti-prothrombin antibodies in the routine laboratory workout of antiphospholipid-positive patients in order to define their thrombotic risk...
  2. ncbi Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome?
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Haemostasis 30:57-62. 2000
    ..Furthermore, they only partially support the notion that anti-beta 2-glycoprotein I and antiprothrombin antibodies may be independent risk factors for thrombosis...
  3. ncbi Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups
    R Bassan
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Hematol J 2:117-26. 2001
    ..So, a prospective validation of the therapeutic efficacy of a protocol (or a component thereof) in specific risk groups is uncommon...
  4. ncbi The epidemiology of the antiphospholipid syndrome: who is at risk?
    G Finazzi
    Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Curr Rheumatol Rep 3:271-6. 2001
    ..The data only partially support the concept that anti-beta 2-GPI and aPT antibodies may be considered as independent risk factors for thrombosis. Further prospective studies are required...
  5. ncbi Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG)
    S Cortelazzo
    Divisione di Ematologia, Ospedali Riuniti di Bergamo, Italy
    Ann Oncol 10:1433-40. 1999
    ....
  6. ncbi Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinic
    R Bassan
    Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy
    Haematologica 84:1088-93. 1999
    ..04). Aiming to minimize this percentage of resistant disease, fractionated cyclophosphamide (f-CY) was then added to the IVAP regimen...
  7. ncbi Treatment of essential thrombocythemia with special emphasis on leukemogenic risk
    G Finazzi
    Division of Hematology, Ospedali Riuniti, Largo Barozzi 1, I 24100 Bergamo, Italy
    Ann Hematol 78:389-92. 1999
    ....
  8. ncbi Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI)
    S Cortelazzo
    Division of Hematology, Ospedali Riuniti di Bergamo, Italy
    Ann Oncol 10:427-32. 1999
    ....
  9. ncbi The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 81:695-700. 1999
    ..In conclusion, the "dRVVT" profile appears to have predictive value with respect to the thrombotic complications suffered by patients with antiphospholipid antibodies...
  10. ncbi Prothrombin as cofactor for antiphospholipids
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Lupus 7:S37-40. 1998
    ..Similarly, most of the studies that measured anti-prothrombin antibodies by ELISA failed to find a significant association with thrombosis. In conclusion, the clinical relevance of these antibodies has not yet been established...
  11. ncbi Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays
    M Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 80:246-9. 1998
    ..Both assays, when negative, make unlikely the presence of the R506Q mutation. Polymerase chain reaction analysis remains, however, to be performed when either test is positive...
  12. ncbi Treatment of polycythemia vera
    T Barbui
    Department of Hematology, Ospedali Riuniti, Bergamo, Italy
    Haematologica 83:143-9. 1998
    ..The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient...
  13. ncbi Antiphospholipid antibodies: predictive value of laboratory tests
    M Galli
    Division of Haematology, Ospedali Riunlti, Bergamo, Italy
    Thromb Haemost 78:75-8. 1997
    ....
  14. ncbi Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies
    M Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 77:486-91. 1997
    ..These findings suggest that anti-prothrombin antibodies resemble aCL antibodies with respect to the behaviour in "in vitro" coagulation reactions and underline the wide heterogeneity of antiphospholipid antibodies...
  15. ncbi Efficacy and safety of hydroxyurea in patients with essential thrombocythemia
    G Finazzi
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Pathol Biol (Paris) 49:167-9. 2001
    ..Sequential multiple chemotherapy, such busulphan followed by HU, should be avoided in any case because of the high risk of secondary leukemias...
  16. ncbi A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
    G Finazzi
    The Ospedali Riuniti, Bergamo, Italy
    J Thromb Haemost 3:848-53. 2005
    ..18; 95% CI 0.92-5.15). CONCLUSIONS: High-intensity warfarin was not superior to standard treatment in preventing recurrent thrombosis in patients with APS and was associated with an increased rate of minor hemorrhagic complications...
  17. ncbi The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants
    M Galli
    Divisione di Ematologia, Ospedali Riuniti di Bergamo Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Institute of Internal Medicine and IRCCS, Maggiore Hospital, Milano, Italy
    Br J Haematol 108:865-70. 2000
    ..No significant correlation was found among the three groups. In conclusion, only the G1691 --> A mutation in the factor V gene was associated with the thrombotic risk of patients with lupus anticoagulants...
  18. ncbi Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers
    T Barbui
    Division of Hematology, Ospedali Riuniti Bergamo, Italy
    Leuk Lymphoma 22:149-60. 1996
    ..However, both IFN and Anagrelide have shown to have frequent and clinically important side effects. Thus, further clinical studies are required to establish their role in the strategy of ET patient treatment...
  19. ncbi Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
    G Finazzi
    Department of Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Leukemia 22:1494-502. 2008
    ..Finally, there is great expectation for novel drugs targeting the constitutively active JAK2/STAT pathway...
  20. ncbi Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders
    G Finazzi
    Division of Hematology, Ospedali Riuniti di Bergamo, Italy
    Lupus 21:747-50. 2012
    ....
  21. ncbi Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
    G Finazzi
    Division of Hematology, Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Leukemia 26:716-9. 2012
    ..These observations carry significant therapeutic implications in these two WHO entities...
  22. ncbi Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
    A Falanga
    Hematology Division, Ospedali Riuniti, Bergamo, Italy
    Blood 96:4261-6. 2000
    ..Blood. 2000;96:4261-4266)..
  23. ncbi How to manage essential thrombocythemia
    G Finazzi
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Leukemia 26:875-82. 2012
    ..Low-risk women are given low-dose aspirin throughout pregnancy and prophylactic low-molecular-weight heparin (LMWH) post partum, whereas LMWH throughout pregnancy and/or interferon-alpha can be required in high-risk cases...
  24. ncbi Recurrence after first cerebral infarction in young adults
    M Camerlingo
    Unit of Neurology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy
    Acta Neurol Scand 102:87-93. 2000
    ..We have investigated recurrence of stroke in a consecutive series of young adults, aged 16 to 45 years, after a first cerebral infarction...
  25. ncbi The treatment of polycythaemia vera: an update in the JAK2 era
    G Finazzi
    Department of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, I 24128, Bergamo, Italy
    Intern Emerg Med 2:13-8. 2007
    ..Nevertheless, these drugs require further clinical experience and, for the time being, should be reserved for selected cases...
  26. ncbi Pathogenesis of antiphospholipid syndrome
    M Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Thromb Res 115:103-7. 2005